Form 4: Inhibrx Biosciences Director, Kristiina Vuori, Acquires Stock Options Following Sanofi Merger

Kristiina Vuori, a director at Inhibrx Biosciences, acquired stock options for 30,000 shares of common stock following the merger with a Sanofi subsidiary.

Summary

• Kristiina Vuori, a director of Inhibrx Biosciences, Inc., filed a Form 4 on May 30, 2024.
• The filing reports a transaction where Vuori acquired stock options to purchase 30,000 shares of Inhibrx Biosciences common stock.
• The stock options were granted following the completion of the merger between Inhibrx, Inc. and a wholly-owned indirect subsidiary of Sanofi.
• The exercise price of the stock options is $15.86 per share.
• The options become fully exercisable on May 30, 2025, contingent upon Vuori's continued service with the company.
• The options expire on May 30, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and aligns the director's interests with the company's success. The merger with Sanofi is also a positive development.

Positives

• The granting of stock options to a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

In the biotechnology industry, stock options are a common form of compensation for directors and executives, aligning their interests with the long-term success of the company, especially following a merger or acquisition.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry, particularly after a merger like the Inhibrx-Sanofi deal.
• Companies like Amgen, Gilead, and Biogen routinely use stock options as part of their executive compensation packages.
• The vesting schedule of one year is fairly standard, aligning with typical industry practices to incentivize continued service.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with the company's performance.
• Employees may see this as a sign of stability following the merger.

Key Dates